Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 10—October 2003
Research

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

Brian Clarke*, Margot Hiltz*, Heather Musgrave*, and Kevin R. Forward*Comments to Author 
Author affiliations: *Dalhousie University and the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Main Article

Table 2

Effect of serial passage on cefoxitin gradient on promoter and attenuator regions and outer membrane protein profiles of laboratory wild type Escherichia colia,b

Strain MIC before serial passage (μg/mL) MIC after serial passage (μg/mL) Outer membrane protein profile
LD1
<2
>32
None
LD2
<2
>32
Omp C-, Omp F-
LD3
<2
16
Omp C-, Omp F-
LD4
<2
>32
Omp C-, Omp F-
LD5
<2
>32
Omp C-, Omp F-
LD6
<2
8
Not done
LD7
<2
4
Not done
LD8
<2
16
Omp C-, Omp F-
LD9
<2
>32
Omp C- , Omp F-
LD10 <2 >32 Decreased production of OmpC/F

aOnly those mutations that arose following serial passage are shown. Some parental strains had mutations initially, which were retained in the mutants.
bNo promoter/attenuator mutations affected β-lactamase production.

Main Article

Page created: January 10, 2011
Page updated: January 10, 2011
Page reviewed: January 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external